IL-6 Blocker Effective Two Years After Withdrawal

]]>(MedPage Today) -- At the recent 2019 American College of Rheumatology meeting in Atlanta, a 2-year extension of the GiACTA trial showed that the benefits of tocilizumab for giant cell arteritis proved durable in nearly half of the patients treated...